Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 326,190 |
|
|||||
| News | - | ||||||
| Day High | 1.98 | Low High |
|||||
| Day Low | 1.855 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Compugen Ltd | CGEN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.02 | 1.05% | 1.92 | 15:41:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.89 | 1.855 | 1.98 | 1.92 | 1.90 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,917 | 326,190 | US$ 1.90 | US$ 620,855 | - | 0.53 - 3.0301 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:50:45 | 20 | US$ 1.92 | USD |
Compugen Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 170.44M | 89.24M | - | 33.46M | -18.75M | -0.21 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Compugen News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.91 | 2.03 | 1.835 | 1.92 | 233,344 | 0.01 | 0.52% |
| 1 Month | 2.555 | 2.57 | 1.8301 | 2.11 | 295,467 | -0.635 | -24.85% |
| 3 Months | 2.41 | 3.0301 | 1.8301 | 2.48 | 513,274 | -0.49 | -20.33% |
| 6 Months | 0.70 | 3.0301 | 0.53 | 2.00 | 1,575,715 | 1.22 | 174.29% |
| 1 Year | 0.60 | 3.0301 | 0.53 | 1.82 | 970,932 | 1.32 | 220.00% |
| 3 Years | 8.81 | 9.20 | 0.51 | 3.03 | 924,182 | -6.89 | -78.21% |
| 5 Years | 3.47 | 19.90 | 0.51 | 6.71 | 912,524 | -1.55 | -44.67% |
Compugen Description
| Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. |
